Among gynecologists with no prior training, the initial cases of laparoscopic radiofrequency ablation of leiomyomas can be performed with rapid onset of surgical confidence and favorable clinical outcomes.
Patient demand for RFA was high, but poor insurance authorization prevented 74% of eligible women from trial participation; 26 women underwent surgery and enrolled. The mean age of participants was 41.5 years (standard deviation (SD) 4.9). Mean operating time was 153 minutes (SD 51) and estimated blood loss was 24cc (SD 40). There were no intraoperative complications and no major adverse decrease in the leiomyoma Symptom Severity Score. After the first procedure performed, 6 was the mean difficulty score (Confidence Interval (CI) 4, 7.5) on a 10 point scale and 89% of surgeons felt "very or somewhat" confident in performing laparoscopic RFA; the score decreased to 4.25 (CI 1.2, 6) after the fourth procedure with all gynecologists reporting surgical confidence.
Conclusions
Laparoscopic RFA of leiomyomas can be introduced into surgical practice with good clinical outcomes for patients. Gynecologists with no prior experience are able to gain confidence and skill with the procedure quickly in <5 cases States. The estimated annual cost of care for women with leiomyomas is $34 billion, with 50% of the cost from lost work and disability related to surgical hospitalization and recovery time. 1 Many women with leiomyomas seek new minimally invasive uterine-sparing treatments with rapid recovery and durable symptom relief that may defray the cost and prolonged disability of traditional leiomyoma surgeries.
Laparoscopic radiofrequency ablation (RFA) of leiomyomas is an outpatient, uterine-preserving, minimally invasive surgery that aims to improve leiomyoma symptoms with minimal operative risks and short recovery time.
The pivotal trial of RFA to gain Federal Drug Administration (FDA) device approval enrolled 134 women and demonstrated significant improvement in leiomyoma-related symptoms and a decrease in leiomyoma volume; 11% of patients underwent additional leiomyoma surgery at 3 years of follow-up. 2 Although the device for RFA of leiomyomas was FDA approved in November 2012, lack of coverage among major insurance carriers limited the use of this procedure during the initial years of market availability. However, in January 2017, RFA was assigned a CPT code by the American Medical Association which has increased coverage authorization by commercial payers and allowed greater uptake of RFA into gynecologic surgical practice. Therefore, there is an urgent or cystectomy), had pelvic infection within the last three months, had a history of pelvic malignancy or radiation, or any implantable metallic device. We also excluded women with a high suspicion for dense pelvic adhesions and any surgical or procedural treatment for leiomyomas within the last three months.
We also excluded women with leiomyoma characteristics that are not amenable to laparoscopic RFA treatment: pedunculated leiomyomas with stalk <25% of the maximum leiomyoma diameter, intracavitary leiomyoma (FIGO Type 0), or the only leiomyoma is submucosal ≥50% intracavitary (FIGO Type 1). Women who desired future fertility were included in the trial after detailed counseling by their physician that the treatment is not FDA approved for women who desire future pregnancy and there is insufficient data to determine the impact of treatment on fertility and pregnancy outcomes. The consent form also listed a possible increase in the risk of adverse pregnancy outcomes including miscarriage, 
RESULTS
Across all five study sites, there were 783 women screened for study participation (Figure 2) . After counseling about the procedure, including the potential for insurance companies to deny authorization for coverage and the long wait times to manage appeals to insurance coverage decisions, 210 (27%) of these women elected to undergo other leiomyoma treatment. Lack of any insurance coverage or a carrier that was accepted at our study sites excluded The study population was racially and ethnically diverse with a mean age of 41.5 years ( Table 1) Two days after surgery, the mean pain score was 3.7 (95% CI 2.97,4.47) and 56% of participants were using opoid pain medication. Pain scores decreased over the next several weeks with a nadir of 1.0 (95% CI 0.42,1.57) at the 3
week follow-up when no participants reported using pain medication. The average time taken off of work was 10.8 days (SD 7.1) and return to usual activities was 9.2 days (SD6.5). Five days after surgery, 34% of participants were back to their usual activities and 50% had returned to work with an increase to 69% return to usual activities and 73% returned to work by 10 days after surgery.
In the 6 weeks following surgery, there were no major adverse events ( 
DISCUSSION
In this analysis of the ULTRA study, we report key clinical outcomes and operator experience during the initial adoption of laparoscopic RFA into leiomyoma surgical practice. A prior study of 40 RFA cases during the "run-in" period of a randomized trial reported surgeon experience, but gynecologists were only assessed after they "felt comfortable" with the procedure, had completed 2-5 cases, and could complete the procedure "safely". 8 In contrast, our trial includes surgical outcomes beginning with the very first case completed among gynecologists with no prior experience using RFA. Therefore, we provide a unique opportunity to assess the learning curve and clinical outcomes during laparoscopic hysterectomy or single-port laparoscopic myomectomy have also been shown to require 45-50 cases to minimize adverse events. 14, 15 In contrast to this high volume of cases, 89% of gynecologists in our study reported being somewhat or very confident in performing the procedure after the very first case of RFA. This confidence level rose to 100% of gynecologists after four procedures, when half of the surgeons felt they no longer required the physician trainer in the operating room. After the first case, gynecologists reported that the procedure was moderately difficult with a score of 6.0 (SD 2.35), but the score dropped quickly to 4.25 (SD 2.22) by the fourth case. RFA for leiomyomas does not require laparoscopic suturing; in ULTRA, general gynecologists were able to learn the procedure quickly and gain confidence and skill in less than five cases.
With the introduction of new surgical techniques, case volume has also been linked to operative outcomes and the rate of adverse events. In large case series of gynecologists learning laparoscopic hysterectomy, the rate of surgical complications decreases over time as the volume of cases increases for each surgeon. [16] [17] [18] In the first 26 cases of RFA performed in our trial, there were no intra-operative complications, conversions to laparotomy, or serious adverse events in the 6 weeks following surgery. However, this is a very small sample size that is underpowered to adequately assess surgical complications.
Operative time in our trial was 2.5 hours, about 40 minutes longer than in the "run-in" phase of 40 cases in a RFA randomized trial (114 min, SD 60 min). 8 Further study is needed to understand how these variables and other factors may impact overall operative time.
In addition to safety and ease of performing the surgery, patient-reported outcomes were favorable during this early use of RFA. Recovery time was rapid; 35% of participants had returned to work 2 days after surgery and 73% by 10 days. At baseline, study participants were highly symptomatic, but by 12 weeks after surgery, all patient-reported outcomes had improved significantly including overall leiomyoma symptoms, heavy bleeding, and sexual health. The 25 point improvement in the UFS-QOL Symptom Severity score is similar to changes in this symptom scale reported in the pivotal trial of laparoscopic RFA 19 , and other trials of uterine-preserving leiomyoma procedures 12 weeks after Treatment. 20, 21 The ULTRA trial highlights the strong demand for new minimally invasive uterine sparing leiomyoma treatments. In a two-year period, 783 women 17 expressed interest in the trial and were screened for study eligibility. Many of these women were planning future pregnancy and seeking alternatives to myomectomy. Currently, the RFA device has not been approved by the FDA for women who desire future fertility because of limited pregnancy outcome data.
The largest case series reported 30 pregnancies in 28 women who had undergone RFA of leiomyoma in clinical trials or post-market practice settings 22 , Among these pregnancies, 26 (86.7%) delivered at term with healthy infants; 50% by cesarean section and 50% by vaginal delivery.
Obstetric complications were noted in 2 patients; one had placenta previa and one had a post-partum hemorrhage in which she expelled a degenerated fibroid per vagina 2 days after cesarean section and required endometrial curettage and 6 units of transfused blood. Additional data is needed with much larger sample size to further evaluate pregnancy outcomes and determine the safety of RFA for women who seek future fertility.
CONCLUSION
Unlike many other new laparoscopic procedures, our results suggest that laparoscopic RFA may be adopted quickly into leiomyoma surgical practice.
Although the sample size is small, we found statistically significant improvements in leiomyoma-related symptoms from baseline to 6 and 12 weeks following surgery, even in the initial cases performed by each provider.
Since the close of the trial, a new visual guidance system has been introduced to assist gynecologists in correctly targeting the RF probe into the leiomyoma.
This support may further decrease the difficulty score, even after the first procedure. One limitation of the study is the single-arm unblinded design which may bias patient-reported outcomes such as changes in leiomyoma symptoms, 441   442   443   444  22   499  500  501  502  503  504  505  506  507  508  509  510  511  512  513  514  515  516  517  518  519  520  521  522  523  524 
